Royalty Pharma Other royalty income receivable decreased by 6.2% to $27.51M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.7%, from $23.79M to $27.51M. Over 5 years (FY 2020 to FY 2025), Other royalty income receivable shows an upward trend with a 37.3% CAGR.
Changes reflect fluctuations in the underlying sales performance of the royalty portfolio and the timing of contractual payment cycles.
This represents royalty income that has been earned based on partner product sales but has not yet been received in cash...
Specific to royalty-based business models; peers report similar accruals based on the reporting lag of pharmaceutical partners.
current_assets_other_royalty_income_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.69M | $13.84M | $15.02M | $14.62M | $17.32M | $19.13M | $19.77M | $22.08M | $18.87M | $21.55M | $22.41M | $22.23M | $23.58M | $24.90M | $26.96M | $23.79M | $27.74M | $28.90M | $29.32M | $27.51M |
| QoQ Change | — | +29.5% | +8.5% | -2.7% | +18.4% | +10.5% | +3.3% | +11.7% | -14.6% | +14.2% | +4.0% | -0.8% | +6.1% | +5.6% | +8.3% | -11.8% | +16.6% | +4.2% | +1.4% | -6.2% |
| YoY Change | — | — | — | — | +61.9% | +38.2% | +31.6% | +51.1% | +9.0% | +12.7% | +13.3% | +0.6% | +25.0% | +15.5% | +20.3% | +7.0% | +17.7% | +16.1% | +8.8% | +15.7% |